BTXA Nanotherapy Ltd

Nanoligent

The company develops targeted protein-drug nanoconjugates for oncology patients to treat metastatic tumours by selectively eliminating cells overexpressing the CXCR4 receptor.

Alpha-9 Theranostics

This clinical-stage biotechnology company develops targeted radiopharmaceuticals to treat cancer patients by delivering radiation directly to tumours while sparing healthy tissue.

Galera

This biopharmaceutical company develops small-molecule therapies to reduce the side effects of radiotherapy and improve treatment outcomes for patients with advanced breast cancer.

Applied Biotherapeutics

This company develops platform technologies for delivering low-dose radiation precisely at tumor margins for cancer patients undergoing surgical removal.

Bactheravax

This company develops therapeutic vaccines targeting tumour-associated bacteria to improve treatment sensitivity and immune responses for patients with colorectal and other cancers.

Actithera Group

This company develops radioligand therapies to treat cancer patients by delivering radiation directly to solid tumours while sparing healthy tissue.

Actithera

This biotechnology company develops targeted radioligand therapies to treat cancer patients by delivering radioactive isotopes directly to solid tumours.

GT Medical Technologies

This company produces bioresorbable radiotherapy implants for patients with operable brain tumors to deliver targeted radiation immediately following surgical removal.